RGEN250117P160000
- 10.30
- 0.000.00%
Repligen Newsroom
Repligen Corporation (RGEN) Fell Along With Peers
Repligen Initiated at Hold by Canaccord Genuity
Repligen Analyst Ratings
CCORF Initiates Repligen(RGEN.US) With Hold Rating, Announces Target Price $165
Express News | BioLife Solutions Appoints Tony J. Hunt to Its Board of Directors
Press Release: BioLife Solutions Appoints Tony J. Hunt to Its Board of Directors
Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?
Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Several Factors Lifted Repligen Corporation (RGEN) in Q3
RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating
Repligen Launches Novel AVIPure DsRNA Resin in OPUS Pre-packed Columns
Repligen Insider Sold Shares Worth $3,386,439, According to a Recent SEC Filing
Repligen(RGEN.US) Director Sells US$3.39 Million in Common Stock
$Repligen(RGEN.US)$ Director Hunt Anthony sold 24,246 shares of common stock on Nov 21, 2024 at an average price of $139.67 for a total value of $3.39 million.Source: Announcement What is statement
Express News | Form 144 | Repligen(RGEN.US) Insider Proposes to Sell 3.39 Million in Common Stocks
Repligen | 10-Q: Q3 2024 Earnings Report
Repligen | 10-K/A: Annual report (Amendment)
Repligen | 10-Q/A: Quarterly report (Amendment)
Repligen Analyst Ratings
Wolfe Research Initiates Repligen(RGEN.US) With Hold Rating